Mehdi Farokhnia1,2, Brittney D Browning1, Lorenzo Leggio1,2,3,4. 1. Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research and National Institute on Drug Abuse Intramural Research Program, National Institutes of Health. 2. Center on Compulsive Behaviors, National Institutes of Health, Bethesda. 3. Medication Development Program, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, Maryland. 4. Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, Rhode Island, USA.
Abstract
PURPOSE OF REVIEW: The aim of this study was to provide an update on medication development efforts for alcohol use disorder (AUD) by reviewing recently published (past 2 years) human studies that evaluated medications' effects on alcohol-related outcomes. RECENT FINDINGS: Forty-five publications were found suitable for this review. A variety of compounds have been tested in the past 2 years as potential pharmacological options for AUD, including medications that act on multiple targets (topiramate, aripiprazole, quetiapine), calcium channels (gabapentin), gamma-Aminobutyric acid receptors (baclofen, diazepam), glutamate receptors (ifenprodil, memantine, glycine), nicotinic acetylcholine receptors (varenicline, mecamylamine), α1 adrenergic receptors (prazosin, doxazosin), neuroendocrine pathways (oxytocin, a vasopressin receptor 1b antagonist, a ghrelin receptor inverse agonist) and others (samidorphan, ibudilast, N-acetylcysteine, citoline). Important findings and limitations regarding the effects of these medications on alcohol-related outcomes are discussed. SUMMARY: There is a critical need to increase the armamentarium of medications for AUD. Human laboratory studies may help screen and prioritize promising targets and compounds before running large clinical trials. Given the complexity of AUD and the heterogeneity of afflicted patients, future studies should also investigate potential moderators and predictors of response to each pharmacological intervention.
PURPOSE OF REVIEW: The aim of this study was to provide an update on medication development efforts for alcohol use disorder (AUD) by reviewing recently published (past 2 years) human studies that evaluated medications' effects on alcohol-related outcomes. RECENT FINDINGS: Forty-five publications were found suitable for this review. A variety of compounds have been tested in the past 2 years as potential pharmacological options for AUD, including medications that act on multiple targets (topiramate, aripiprazole, quetiapine), calcium channels (gabapentin), gamma-Aminobutyric acid receptors (baclofen, diazepam), glutamate receptors (ifenprodil, memantine, glycine), nicotinic acetylcholine receptors (varenicline, mecamylamine), α1 adrenergic receptors (prazosin, doxazosin), neuroendocrine pathways (oxytocin, a vasopressin receptor 1b antagonist, a ghrelin receptor inverse agonist) and others (samidorphan, ibudilast, N-acetylcysteine, citoline). Important findings and limitations regarding the effects of these medications on alcohol-related outcomes are discussed. SUMMARY: There is a critical need to increase the armamentarium of medications for AUD. Human laboratory studies may help screen and prioritize promising targets and compounds before running large clinical trials. Given the complexity of AUD and the heterogeneity of afflicted patients, future studies should also investigate potential moderators and predictors of response to each pharmacological intervention.
Authors: Joseph P Schacht; Konstantin E Voronin; Patrick K Randall; Raymond F Anton Journal: Neuropsychopharmacology Date: 2017-12-06 Impact factor: 7.853
Authors: Stephanie S O'Malley; Allen Zweben; Lisa M Fucito; Ran Wu; Mary E Piepmeier; David M Ockert; Krysten W Bold; Ismene Petrakis; Srinivas Muvvala; Peter Jatlow; Ralitza Gueorguieva Journal: JAMA Psychiatry Date: 2018-02-01 Impact factor: 21.596
Authors: Lindsay M Squeglia; Rachel L Tomko; Nathaniel L Baker; Erin A McClure; George A Book; Kevin M Gray Journal: Drug Alcohol Depend Date: 2018-02-01 Impact factor: 4.492
Authors: Kirsten C Morley; Andrew Baillie; Isabel Fraser; Ainsley Furneaux-Bate; Glenys Dore; Michael Roberts; Ahmed Abdalla; Nghi Phung; Paul S Haber Journal: Br J Psychiatry Date: 2018-05-02 Impact factor: 9.319
Authors: Carolina L Haass-Koffler; Kimberly Goodyear; William H Zywiak; Lorenzo Leggio; George A Kenna; Robert M Swift Journal: Alcohol Alcohol Date: 2018-05-01 Impact factor: 2.826
Authors: Kirsten C Morley; Jim Lagopoulos; Warren Logge; Kate Chitty; Andrew Baillie; Paul S Haber Journal: Front Psychiatry Date: 2018-09-04 Impact factor: 4.157
Authors: Mehdi Farokhnia; Christopher T Rentsch; Vicky Chuong; M Adrienne McGinn; Sophie K Elvig; Eliza A Douglass; Luis A Gonzalez; Jenna E Sanfilippo; Renata C N Marchette; Brendan J Tunstall; David A Fiellin; George F Koob; Amy C Justice; Lorenzo Leggio; Leandro F Vendruscolo Journal: Mol Psychiatry Date: 2022-09-20 Impact factor: 13.437
Authors: John C Crabbe; Angela R Ozburn; Robert J Hitzemann; Stephanie E Spence; Wyatt R Hack; Jason P Schlumbohm; Pamela Metten Journal: Brain Behav Immun Health Date: 2020-03-19
Authors: Reagan R Wetherill; Nathaniel Spilka; Kanchana Jagannathan; Paige Morris; Danielle Romer; Timothy Pond; Kevin G Lynch; Teresa R Franklin; Henry R Kranzler Journal: Neuropsychopharmacology Date: 2021-02-08 Impact factor: 7.853
Authors: Vincent N Marty; Mehdi Farokhnia; Joseph J Munier; Yatendra Mulpuri; Lorenzo Leggio; Igor Spigelman Journal: Front Neurosci Date: 2020-12-23 Impact factor: 4.677
Authors: Armando G Salinas; Jacob A Nadel; Yolanda Mateo; Thanh Huynh; Shana M Augustin; Karel Pacak; David M Lovinger Journal: Int J Mol Sci Date: 2022-09-20 Impact factor: 6.208
Authors: Mehdi Farokhnia; Kelly M Abshire; Aaron Hammer; Sara L Deschaine; Anitha Saravanakumar; Enoch Cobbina; Zhi-Bing You; Carolina L Haass-Koffler; Mary R Lee; Fatemeh Akhlaghi; Lorenzo Leggio Journal: Int J Neuropsychopharmacol Date: 2021-07-14 Impact factor: 5.176
Authors: Mehdi Farokhnia; Jeanelle Portelli; Mary R Lee; Gray R McDiarmid; Vikas Munjal; Kelly M Abshire; Jillian T Battista; Brittney D Browning; Sara L Deschaine; Fatemeh Akhlaghi; Lorenzo Leggio Journal: Brain Res Date: 2020-04-24 Impact factor: 3.252